CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT
|
|
- Kelley Watts
- 6 years ago
- Views:
Transcription
1 CANADA: INTERNATIONAL TREATIES AND THE PROMISE OF THE PATENT By Thomas Kurys July 24, DLA Piper Canada LLP July 24,
2 To Be Discussed 1 Comprehensive Economic and Trade Agreement 2 Utility and the Promise of the Patent DLA Piper Canada LLP July 24,
3 1 Comprehensive Economic and Trade Agreement
4 Comprehensive Economic and Trade Agreement What is CETA? Free-trade agreement between Canada and the European Union Will eliminate 98% of the tariffs between Canada and the EU Signed by Canada on 30 October 2016 Bill tabled on October 31, 2016 (Bill C-30) Received Royal Ascent on May 16, 2017 Provisional application to come into effect on September 21, 2017 Includes provisions affecting Canada s patent laws DLA Piper Canada LLP July 24,
5 CETA: Supplementary Patent Protection Sui Generis Protection for Pharma/Biopharma Products Currently no mechanism for pharma/biopharma patentees to extend the patent term as a result of delays in obtaining market approval Bill C-30 will amend the Patent Act to add the concept of patent term restoration for regulatory delays as a Certificate of Supplementary Protection Could effectively extend the patentee s monopoly by up to two years DLA Piper Canada LLP July 24,
6 CETA: Substantive Legislative Modifications Amendments to PM(NOC) Regulations Patented Medicines (Notice of Compliance) Regulations Linkage provisions for regulatory approval of generic drugs and biosimilars Proposed Regulations Amending the Patented Medicines published in Canada Gazette on July 15, 2017 process to be changed from an application to a trial with full right of appeal DLA Piper Canada LLP July 24,
7 2 Utility and the Promise of the Patent
8 The fall of the Promise of the Patent doctrine AstraZeneca Canada Inc. v Apotex Inc., 2017 SCC 36 (June 30, 2017) Considered the promise of the patent doctrine a controversial judge-made approach to the question of patent utility unique to Canada many argued it was out of step with the law in other countries held: the promise doctrine is not good law DLA Piper Canada LLP July 24,
9 What was the Promise of the Patent? invention means any new and useful art, process, machine, manufacture or composition of matter, or any new and useful improvement in any art, process, machine, manufacture or composition of matter (Section 2 of the Patent Act) Where the specification does not promise a specific result, no particular level of utility is required; a mere scintilla of utility will suffice. However, where the specification sets out an explicit promise, utility will be measured against that promise. Eli Lilly v Novopharm, 2010 FCA DLA Piper Canada LLP July 24,
10 Promise Doctrine What was the big deal? Innovators: Labelled as innovation killing Promise Doctrine Cloud of uncertainty Imposes subjective utility standard that is arbitrary and unpredictable Invalidating patents on the basis of lack of utility despite invention at issue actually has a high degree of utility Response: Constraining innovators from overpromising is a reasonable approach to preserving the core policy objectives of patent law that: serve to create consistency and clarity in the bargain struck between innovators and the public Justice Rennie, AstraZeneca v Apotex, 2014 FC DLA Piper Canada LLP July 24,
11 Eli Lilly v Canada NAFTA Challenge On June 13, 2013, Eli Lilly initiated a $500 million CAD claim under NAFTA against the Government of Canada Decision: March 16, 2017 Heart of the claim: Use of the promise doctrine to invalidate patents in Canadian courts for lacking the level of utility promised in the patent specification Lilly s Canadian patents directed to Zyprexa and Strattera were invalidated under this doctrine Lilly alleged that Canada s utility test was contrary to NAFTA DLA Piper Canada LLP July 24,
12 Eli Lilly v Canada NAFTA Challenge Tribunal sided with Canadian government promise doctrine did not represent a dramatic change in Canadian patent law Canada s law on utility underwent incremental and evolutionary changes Eli Lilly s legitimate expectations were not violated by application of doctrine Tribunal s decision came out three months before Supreme Court of Canada decision declaration the promise doctrine not good law DLA Piper Canada LLP July 24,
13 Promise Doctrine - the beginning of the end Nexium (esomeprazole) AstraZeneca Canada v Apotex, 2014 FC 638, 2015 FCA 158 Lower Court held that the patent promised more than it could provide Promised utility of the claims comprised three elements, including improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile This element was not demonstrated by the Canadian filing date for the patent, and the Court held it was also not soundly predictable as of that date Court ultimately held that there is no heightened disclosure in sound prediction cases, except in the context of new use patents Affirmed by Federal Court of Appeal Appealed to the Supreme Court DLA Piper Canada LLP July 24,
14 SCC: promise doctrine is abolished Supreme Court allowed the appeal and abolished the promise doctrine (AstraZeneca Canada Inc. v Apotex Inc., 2017 SCC 36 - June 30, 2017) Approach taken by the lower courts was overly onerous for patentees in that: there was a heightened standard of utility which was applied if there was a promise found in the patent specification, and the approach required a patentee to meet all promises where there are multiple, expressed promises of utility. DLA Piper Canada LLP July 24,
15 SCC: promise doctrine is abolished The Promise Doctrine is flawed: It conflated the utility requirement under section 2 of the Patent Act with the disclosure requirement under section 27(3). Under section 27(3), the inventor must fully disclose the invention to enable the skilled person to use or construct the invention when the monopoly period has expired. Section 2, on the other hand, requires the subject-matter of the invention to be useful the bounds of which are defined by the claims. The effect of the Promise Doctrine was to undermine the disclosure requirement by discouraging fulsome disclosure for risk of invalidity on the basis of an unintentional overstatement of even a single use. DLA Piper Canada LLP July 24,
16 The Proper Approach to Utility Courts are to apply the following analysis: First, courts must identify the subject-matter of the invention as claimed in the patent. Second, courts must ask whether that subject-matter is useful is it capable of a practical purpose (i.e. an actual result)? A mere scintilla of utility will do DLA Piper Canada LLP July 24,
17 Example Invention: an innovative genetically modified microbe for the purification of waste water. Patent specification: discusses the ability of the microbe to improve nitrate reduction in waste waters. states that the microbe of the invention would result in 90% purification Under the new regime since 2017 SCC 36, a scintilla of utility demonstrated for this purpose should suffice, regardless of any language in the specification about desired or expected levels of purification. Under the old "promise" approach the patent could fail if this "promised" efficiency level had not been demonstrated or could not have been soundly predicted. DLA Piper Canada LLP July 24,
18 Implications Supreme Court Decision viewed as a big win for rights holders generally. Established a clear threshold for patent utility that is lower than the Federal Courts had applied under the Promise Doctrine. By restricting the assessment of utility to the claims, full, frank, and good faith disclosure in the specification will not jeopardize patent rights, if challenged. However, overpromising is still a mischief: disclosure that is not correct or full, or states an unsubstantiated use, may be insufficient overly broad claims may be invalid overpromising in a specification may void a patent under s. 53 (omission or addition willfully made for the purpose of misleading) Thus, decision may shift focus of patent attacks to other areas DLA Piper Canada LLP July 24,
19 DLA Piper (Canada) LLP is part of DLA Piper, a global law firm operating through various separate and distinct legal entities. For further information please refer to the Legal Notices section at DLA Piper Canada LLP July 24,
Questionnaire. Apotex-Inc. v Sanofi-Aventis
Questionnaire Apotex-Inc. v Sanofi-Aventis 1. Introduction In Apotex Inc. v Sanofi-Aventis, the Supreme Court of Canada has granted leave to Apotex Inc to appeal the validity of a Canadian pharmaceutical
More informationSUPREME COURT OF CANADA. APPEAL HEARD: November 8, 2016 JUDGMENT RENDERED: June 30, 2017 DOCKET: 36654
SUPREME COURT OF CANADA CITATION: AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36 APPEAL HEARD: November 8, 2016 JUDGMENT RENDERED: June 30, 2017 DOCKET: 36654 BETWEEN: AstraZeneca Canada Inc., AstraZeneca
More informationIssues of Patent Drafting in Canadian Patent Law: A Unique Paradigm. By Livia Aumand & John Norman. Gowling WLG (Canada) LLP
Issues of Patent Drafting in Canadian Patent Law: A Unique Paradigm By Livia Aumand & John Norman Gowling WLG (Canada) LLP In the past 10-15 years, there has been an evolution in Canadian patent law that
More informationELI LILLY AND COMPANY. Disputing Investor, -and- THE GOVERNMENT OF CANADA. Disputing Party
ELI LILLY AND COMPANY Disputing Investor, -and- THE GOVERNMENT OF CANADA Disputing Party NOTICE OF INTENT TO SUBMIT A CLAIM TO ARBITRATION UNDER NAFTA CHAPTER ELEVEN (Strattera and Zyprexa) GOWLING LAFLEUR
More informationIN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976)
IN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976) BETWEEN: ELI LILLY AND COMPANY Claimant/Investor AND: GOVERNMENT
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Canada Second medical use or indication claims Matthew ZISCHKA Santosh CHARI Carol HITCHMANN Roseanne CALDWELL Charles
More informationEarly Resolution Mechanism for Patent Disputes Regarding Approved Drug Products - Canada
Early Resolution Mechanism for Patent Disputes Regarding Approved Drug Products - Canada Pharma Workshop 4 AIPPI Toronto September 16, 2014 Warren Sprigings Direct Dial: +1-416-777-2273 warren@sprigings.com
More informationThe Patented Medicines (Notice of Compliance) Regulations: What patents are eligible to be listed on the register?
The Patented Medicines (Notice of Compliance) Regulations: What patents are eligible to be listed on the register? Edward Hore Hazzard & Hore 141 Adelaide Street West, Suite 1002 Toronto, ON M5H 3L5 (416)
More informationThe use of prosecution history in post-grant patent proceedings. The Groups are invited to answer the following questions under their national laws.
Question Q229 National Group: Canada Title: The use of prosecution history in post-grant patent proceedings Contributors: ZISCHKA, Matthew SOFIA, Michel HAMILTON, J. Sheldon HARRIS, John ROWAND, Fraser
More informationIndexed As: Dow Chemical Co. et al. v. Nova Chemicals Corp. Federal Court O'Keefe, J. September 5, 2014.
The Dow Chemical Company, Dow Global Technologies Inc. and Dow Chemical Canada ULC (plaintiffs) v. Nova Chemicals Corporation (defendant) (T-2051-10; 2014 FC 844) Indexed As: Dow Chemical Co. et al. v.
More informationImproper Selection: A Separate Ground of Patent Invalidity in Canada?
Osgoode Hall Review of Law and Policy Volume 3 Number 1 Volume 3, Number 1 (March 2010) Article 2 2010 Improper Selection: A Separate Ground of Patent Invalidity in Canada? Anna Wilkinson Follow this and
More informationExamination Practice Respecting Purposive Construction PN
5 Whirlpool at paragraph 49 1 March 8, 2013 To all examiners: Examination Practice Respecting Purposive Construction PN2013-02 In Canada (Attorney General) v Amazon.com Inc., 2011 FCA 328 [Amazon FCA],
More informationUNCT/14/2) ELI LILLY AND COMPANY
In the Arbitration under the Arbitration Rules of the United Nations Commission on International Trade Law and the North American Free Trade Agreement (Case No. UNCT/14/2) ELI LILLY AND COMPANY Claimant
More informationQuestionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal
National Group: Hungarian Title: Reporter: Contributors: Questionnaire Apotex Inc. v Sanofi-Aventis Proposed AIPPI intervention Supreme Court of Canada appeal Dr. PETHŐ, Árpád Dr. PETHŐ, Árpád, MOLNÁR,
More informationWhere are we now with plausibility?
/0/7 Where are we now with plausibility? Jin Ooi, Allen & Overy LLP (UK) Monday April 7 What s the big deal with plausibility? For the first time since the first edition in 188, the 18 th edition of Terrell
More informationPURDUE PHARMA AND EURO-CELTIQUE S.A. and PURDUE PHARMA. and COLLEGIUM PHARMACEUTICAL, INC. MAPI LIFE SCIENCES CANADA INC. AND THE MINISTER OF HEALTH
Date: 20180221 Dockets: T-856-17 T-824-17 Citation: 2018 FC 199 Ottawa, Ontario, February 21, 2018 PRESENT: The Honourable Mr. Justice O'Reilly Docket: T-856-17 BETWEEN: PURDUE PHARMA AND EURO-CELTIQUE
More informationAre the Patented Medicines (Notice of Compliance) Regulations Working?
Are the Patented Medicines (Notice of Compliance) Regulations Working? Edward Hore Hazzard & Hore 141 Adelaide Street West, Suite 1002 Toronto, ON M5H 3L5 (416) 868-1340 edhore@hazzardandhore.com March
More informationTEVA CANADA LIMITED. and PFIZER CANADA INC., PFIZER INC. AND PFIZER IRELAND PHARMACEUTICALS REASONS FOR ORDER AND ORDER
Date: 20140122 Docket: T-2280-12 Citation: 2014 FC 69 Ottawa, Ontario, January 22, 2014 PRESENT: The Honourable Mr. Justice de Montigny BETWEEN: TEVA CANADA LIMITED Plaintiff and PFIZER CANADA INC., PFIZER
More informationTalking points on recent article
(A-2017-01612) - Page: 192 Talking points on recent article The grant of a patent enhances innovation in two ways: 1. The inventor is given a 20-year monopoly which acts as an incentive to invent; and,
More informationComparative Analysis of the U.S. Intellectual Property Proposal and Peruvian Law
!!! Dangers for Access to Medicines in the Trans-Pacific Partnership Agreement: Comparative Analysis of the U.S. Intellectual Property Proposal and Peruvian Law ! Issue US TPPA Proposal Andean Community
More informationPeople s Republic of China State Intellectual Property Office of China
[English translation by WIPO] Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Office: People s Republic of China
More informationThe Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act
FEBRUARY 2015 The Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act Authors: Ki Young Kim, Hyunsuk Jin, Samuel SungMok Lee Pursuant to the implementation of the Korea-US
More informationAMICUS CURIAE SUBMISSION Eli LILLY AND COMPANY v. THE GOVERNMENT OF CANADA
AMICUS CURIAE SUBMISSION Eli LILLY AND COMPANY v. THE GOVERNMENT OF CANADA I. Introduction In September 2013, the Claimant Eli Lilly and Company (Lilly) launched a CDN $ 500 million claim against the Government
More information50 Victoria St. confirmation by mail Gatineau, Quebec K1A 0C9
- 1 - September 8, 2017 The Commissioner of Patents, submitted electronically 50 Victoria St. confirmation by mail Gatineau, Quebec K1A 0C9 Dear Commissioner: Attn: A. Lajoie Re: Proposed Patent Rules
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
Questionnaire on Exceptions and Limitations to Patent Rights The answers to this questionnaire have been provided on behalf of: Country: Australia... Office: IP Australia... Person to be contacted: Name:
More informationLATVIA Patent Law adopted on 15 February 2007, with the changes of December 15, 2011
LATVIA Patent Law adopted on 15 February 2007, with the changes of December 15, 2011 TABLE OF CONTENTS Chapter I General Provisions Section 1. Terms used in this Law Section 2. Purpose of this Law Section
More informationTop Ten Tips for Dealing with Business Method Patents in Canada
Top Ten Tips for Dealing with Business Method Patents in Canada Sep 01, 2011 Top Ten By Christopher Van Barr Grant Tisdall This resource is sponsored by: By Christopher Van Barr and Grant Tisdall, Gowling
More informationBRISTOL-MYERS SQUIBB CANADA CO. and BRISTOL-MYERS SQUIBB HOLDINGS IRELAND. and. APOTEX INC. and THE MINISTER OF HEALTH
Date: 20170918 Docket: A-106-17 Citation: 2017 FCA 190 CORAM: WEBB J.A. NEAR J.A. GLEASON J.A. BETWEEN: BRISTOL-MYERS SQUIBB CANADA CO. and BRISTOL-MYERS SQUIBB HOLDINGS IRELAND Appellants and APOTEX INC.
More informationCompilation date: 24 February Includes amendments up to: Act No. 61, Registered: 27 February 2017
Patents Act 1990 No. 83, 1990 Compilation No. 41 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017 This compilation includes commenced amendments
More informationELI LILLY AND COMPANY
Under the Arbitration Rules of the United Nations Commission on International Trade Law and the North American Free Trade Agreement (Case No. UNCT/14/2) ELI LILLY AND COMPANY Claimant v. GOVERNMENT OF
More informationIntellectual Property Laws Amendment Act 2015
Intellectual Property Laws Amendment Act 2015 No. 8, 2015 An Act to amend legislation relating to intellectual property, and for related purposes Note: An electronic version of this Act is available in
More informationNote: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail.
Note: When any ambiguity of interpretation is found in this provisional translation, the Japanese text shall prevail. (Applied to any applications to register a patent term extension filed on or after
More informationThis document gives a brief summary of the patent application process. The attached chart shows the most common patent protection routes.
The patent system Introduction This document gives a brief summary of the patent application process. The attached chart shows the most common patent protection routes. Patents protect ideas and concepts
More informationPROBABLE UTILITY* Robert H.C. MacFarlane** ABSTRACT
PROBABLE UTILITY* Robert H.C. MacFarlane** ABSTRACT This article discusses the legal requirements for making a sound prediction of utility and for disclosing an invention based on such a prediction. It
More informationThe Patents Act 1977 (as amended)
The Patents Act 1977 (as amended) An unofficial consolidation produced by Patents Legal Section 17 December 2007 UK Intellectual Property Office is an operating name of the Patent Office 1 Note to users
More informationAUSTRALIA Patents Act 1990 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017
AUSTRALIA Patents Act 1990 Compilation date: 24 February 2017 Includes amendments up to: Act No. 61, 2016 Registered: 27 February 2017 TABLE OF CONTENTS Chapter 1. Introductory 1 Short title 2 Commencement
More informationOrdinary or Extraordinary: The NOC Regulations
Ordinary or Extraordinary: The NOC Regulations Bill Richardson Partner McCarthy Tétrault LLP (Toronto) Co-authors: Jacob Glick, Meighan Leon and Tamara Ramsey Associates McCarthy Tétrault LLP March 29-30,
More informationRespecting Patent Rights: Model Behavior for Patent Owners
IPO LITIGATION PRINCIPLES TASK FORCE: WHITE PAPER Revised: 03/06/2007 Part I. Introduction 2007 Intellectual Property Owners Association (IPO) Disclaimer: This paper is presented for discussion purposes
More informationThe America Invents Act : What You Need to Know. September 28, 2011
The America Invents Act : What You Need to Know September 28, 2011 Presented by John B. Pegram J. Peter Fasse 2 The America Invents Act (AIA) Enacted September 16, 2011 3 References: AIA = America Invents
More informationETHIOPIA A PROCLAMATION CONCERNING INVENTIONS, MINOR INVENTIONS AND INDUSTRIAL DESIGNS PROCLAMATION NO. 123/1995 ENTRY INTO FORCE: May 10, 1995
ETHIOPIA A PROCLAMATION CONCERNING INVENTIONS, MINOR INVENTIONS AND INDUSTRIAL DESIGNS PROCLAMATION NO. 123/1995 ENTRY INTO FORCE: May 10, 1995 TABLE OF CONTENTS CHAPTER ONE General Provisions 1. Short
More informationHUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015
HUNGARY Patent Act Act XXXIII of 1995 as consolidated on March 01, 2015 TABLE OF CONTENTS PART I INVENTIONS AND PATENTS Chapter I SUBJECT MATTER OF PATENT PROTECTION Article 1 Patentable inventions Article
More informationOFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 REPUBLICATION PATENT LAW NO.64/1991 1
OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 REPUBLICATION PATENT LAW NO.64/1991 1 CHAPTER I - GENERAL PROVISIONS Art. 1 - (1) The rights in inventions shall be recognized and protected on
More informationROMANIA Patent Law NO.64/1991 OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014
ROMANIA Patent Law NO.64/1991 OFFICIAL GAZETTE OF ROMANIA, PART I, NO.613/19 AUGUST 2014 TABLE OF CONTENTS CHAPTER I - GENERAL PROVISIONS Art. 1 Art. 2 Art. 3 Art. 4 Art. 5 CHAPTER II - PATENTABLE INVENTIONS
More informationCongress Passes Historic Patent Reform Legislation
Congress Passes Historic Patent Reform Legislation America Invents Act Transitions U.S. Patent System from a First-to-Invent to First-Inventor-to-File System, Overhauls Post-Issue Review Proceedings and
More informationEUROPEAN GENERIC MEDICINES ASSOCIATION
EUROPEAN GENERIC MEDICINES ASSOCIATION POSITION PAPER POSITION PAPER ON THE REVIEW OF DIRECTIVE 2004/48/EC ON THE ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS JUNE 2011 EGA EUROPEAN GENERIC MEDICINES ASSOCIATION
More information4. COMPARISON OF THE INDIAN PATENT LAW WITH THE PATENT LAWS IN U.S., EUROPE AND CHINA
4. COMPARISON OF THE INDIAN PATENT LAW WITH THE PATENT LAWS IN U.S., EUROPE AND CHINA Provisions of the Indian patent law were compared with the relevant provisions of the patent laws in U.S., Europe and
More informationThe Third Amendment to the Patent Law of China. On December 27, 2008, the Standing Committee of the National People's
The Third Amendment to the Patent Law of China On December 27, 2008, the Standing Committee of the National People's Congress adopted the third amendment to the Patent Law of the People's Republic of China,
More informationLAWS OF MALAWI PATENTS CHAPTER 49:02 CURRENT PAGES
PATENTS CHAPTER 49:02 PAGE CURRENT PAGES L.R.O. 1 4 1/1986 5 10 1/1968 11 12 1/1986 13 64 1/1968 65 68 1/1970 69-86 1/1968 87 88 1/1970 89 90 1/1993 91 108 1/1968 109 112 1/1993 112a 1/1993 113 114 1/1968
More informationTRIPS Article 28 Rights Conferred. 1. A patent shall confer on its owner the following exclusive rights:
TRIPS Article 28 Rights Conferred 1. A patent shall confer on its owner the following exclusive rights: (a) where the subject matter of a patent is a product, to prevent third parties not having the owner
More informationUS-China Business Council Comments on the Draft Measures for the Compulsory Licensing of Patents
US-China Business Council Comments on the Draft Measures for the Compulsory Licensing of Patents The US-China Business Council (USCBC) and its member companies appreciate the opportunity to submit comments
More informationIn the Arbitration under Chapter 11 of the North American Free Trade Agreement and the UNCITRAL Arbitration Rules. Eli Lilly and Company.
Case No. UNCT/14/2 In the Arbitration under Chapter 11 of the North American Free Trade Agreement and the UNCITRAL Arbitration Rules BETWEEN: Eli Lilly and Company CLAIMANT/INVESTOR - and - Government
More informationIn re Metoprolol Succinate Obviousness-Type Double Patenting Walter B. Welsh St. Onge Steward Johnston & Reens LLC Stamford, Connecticut
In re Metoprolol Succinate Obviousness-Type Double Patenting Walter B. Welsh St. Onge Steward Johnston & Reens LLC Stamford, Connecticut I. INTRODUCTION In Metoprolol Succinate the Court of Appeals for
More informationThe methods and procedures described must be directly applicable to production.
National Patent Administration Argentina Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 3 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation
More informationTHE PATENT LAW 1. GENERAL PROVISIONS. Article 1. This Law shall regulate the legal protection of inventions by means of patents.
THE PATENT LAW 1. GENERAL PROVISIONS Article 1 This Law shall regulate the legal protection of inventions by means of patents. Article 2 This Law shall also apply to the sea and submarine areas adjacent
More informationLexisNexis Expert Commentaries David Heckadon on the Differences Between US and Canadian Patent Prosecution
David Heckadon on the Differences Between US and Canadian Patent Prosecution Research Solutions December 2007 The following article summarizes some of the important differences between US and Canadian
More informationIN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976)
IN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976) BETWEEN: ELI LILLY AND COMPANY Claimant/Investor AND: GOVERNMENT
More informationINTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012
INTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012 AUTHOR: MICHAEL CAINE - PARTNER, DAVIES COLLISON CAVE Michael is a fellow and council member of the Institute of Patent and Trade Mark Attorneys
More informationFINAL PROPOSAL OF THE ACT ON AMENDMENTS TO THE PATENT ACT
FINAL PROPOSAL OF THE ACT ON AMENDMENTS TO THE PATENT ACT In the Patent Act ( Official Gazette Nos. 173/2003, 87/2005, 76/2007, 30/2009, 128/10 and 49/2011), after Article 1, Articles 1.a and 1.b are added
More informationAPPENDIX 1 THE CURRENT AUSTRALIAN TESTS SUFFICIENCY
APPENDIX 1 THE CURRENT AUSTRALIAN TESTS SUFFICIENCY 1. The decisions of two differently constituted High Courts in Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd (2001) 207 CLR
More informationEuropean Commission Questionnaire on the Patent System in Europe
European Commission Questionnaire on the Patent System in Europe Response by: Eli Lilly and Company Contact: Mr I J Hiscock Director - European Patent Operations Eli Lilly and Company Limited Lilly Research
More informationU.S. Patent Law Reform The America Invents Act
U.S. Patent Law Reform The America Invents Act August 15, 2011 John B. Pegram Fish & Richardson What s New in 2011? Patent Law Reform is high on Congressional agenda A desire to legislate Bipartisan Patent
More informationSuzannah K. Sundby. canady + lortz LLP. David Read. Differences between US and EU Patent Laws that Could Cost You and Your Startup.
Differences between US and EU Patent Laws that Could Cost You and Your Startup Suzannah K. Sundby United States canady + lortz LLP Europe David Read UC Center for Accelerated Innovation October 26, 2015
More informationInnovation Act (H.R. 9) and PATENT Act (S. 1137): A Comparison of Key Provisions
Innovation Act (H.R. 9) and PATENT Act (S. 1137): A Comparison of Key Provisions TOPIC Innovation Act H.R. 9 PATENT Act S. 1137 Post Grant Review ( PGR ) Proceedings Claim Construction: Each patent claim
More informationAIPPI Study Question - Patentability of computer implemented inventions
Study Question Submission date: June 19, 2017 Sarah MATHESON, Reporter General Jonathan P. OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants
More informationRecent developments in US law: Remedies and damages for improper patent listings in the FDA s Orange Book
Daniel G. Brown is a partner in the New York law firm Frommer Lawrence & Haug, LLP, and practises extensively in the Hatch Waxman area. He has been practising in New York since 1993 in the patent and intellectual
More informationThe EU-Canada Comprehensive Economic and Trade Agreement (CETA) Opening up a wealth of opportunities for people in the Czech Republic
The EU-Canada Comprehensive Economic and Trade Agreement (CETA) Opening up a wealth of opportunities for people in the Czech Republic CETA will benefit people across the Czech Republic It'll do so by:
More informationUnited Kingdom. By Penny Gilbert, Kit Carter and Stuart Knight, Powell Gilbert LLP
Powell Gilbert LLP United Kingdom United Kingdom By Penny Gilbert, Kit Carter and Stuart Knight, Powell Gilbert LLP Q: What options are open to a patent owner seeking to enforce its rights in your jurisdiction?
More informationHigh-Tech Patent Issues
August 6, 2012 High-Tech Patent Issues On June 4, 2013, the White House Task Force on High-Tech Patent Issues released its Legislative Priorities & Executive Actions, designed to protect innovators in
More informationWHAT TO EXPECT WHEN YOU RE EXPECTING A PATENT By R. Devin Ricci 1
WHAT TO EXPECT WHEN YOU RE EXPECTING A PATENT By R. Devin Ricci 1 The general outlay of this guide is to present some of the who, what, where, when, and why of the patent system in order to be able to
More information(Acts whose publication is obligatory) concerning the creation of a supplementary protection certificate for medicinal products
2. 7. 92 Official Journal of the European Communities No L 182/ 1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary
More informationPATENT DISCLOSURE: Meeting Expectations in the USPTO
PATENT DISCLOSURE: Meeting Expectations in the USPTO Robert W. Bahr Acting Associate Commissioner for Patent Examination Policy United States Patent and Trademark Office 11/17/2016 1 The U.S. patent system
More informationIN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976)
IN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976) BETWEEN: ELI LILLY AND COMPANY AND: Claimant/Investor GOVERNMENT
More informationIntellectual Property Laws Amendment Bill 2013 No., 2013
00-0-0-0 The Parliament of the Commonwealth of Australia HOUSE OF REPRESENTATIVES Presented and read a first time Intellectual Property Laws Amendment Bill 0 No., 0 (Industry, Innovation, Climate Change,
More informationPatent Prosecution in View of The America Invents Act. Overview
Patent Prosecution in View of The America Invents Act Courtenay C. Brinckerhoff David Dutcher Paul S. Hunter 2 Overview First-To-File (new 35 U.S.C. 102) Derivation Proceedings New Proceedings For Patent
More information24 Criteria for the Recognition of Inventors and the Procedure to Settle Disputes about the Recognition of Inventors
24 Criteria for the Recognition of Inventors and the Procedure to Settle Disputes about the Recognition of Inventors Research Fellow: Toshitaka Kudo Under the existing Japanese laws, the indication of
More informationPATENT ACT (UNOFFICIAL CLEAR TEXT) I. GENERAL PROVISIONS
PATENT ACT NN 173/03, 31.10.2003. (in force from January 1, 2004) *NN 87/05, 18.07.2005. (in force from July 18, 2005) **NN 76/07, 23.07.2007. (in force from July 31, 2007) ***NN 30/09, 09.03.2009. (in
More informationAn introduction to European intellectual property rights
An introduction to European intellectual property rights Scott Parker Adrian Smith Simmons & Simmons LLP 1. Patents 1.1 Patentable inventions The requirements for patentable inventions are set out in Article
More informationSection 1: General. This question does not imply that the topic of exclusions from patentability is dealt with in this question exhaustively.
Section 1: General 1. As background for the exceptions and limitations to patents investigated in this questionnaire, what is the legal standard used to determine whether an invention is patentable? If
More information2016 Study Question (Patents)
2016 Study Question (Patents) Submission date: 3rd May 2016 Sarah MATHESON, Reporter General John OSHA and Anne Marie VERSCHUUR, Deputy Reporters General Yusuke INUI, Ari LAAKKONEN and Ralph NACK, Assistants
More informationEXPLANATORY NOTES ON THE PATENT LAW TREATY AND REGULATIONS UNDER THE PATENT LAW TREATY * prepared by the International Bureau
EXPLANATORY NOTES ON THE PATENT LAW TREATY AND REGULATIONS UNDER THE PATENT LAW TREATY * prepared by the International Bureau * These Notes were prepared by the International Bureau of the World Intellectual
More informationTHE PATENT LAW 1 I INTRODUCTORY PROVISIONS. 1. Subject Matter of Regulation and Definitions. Subject Matter of Regulation.
THE PATENT LAW 1 I INTRODUCTORY PROVISIONS 1. Subject Matter of Regulation and Definitions Subject Matter of Regulation Article 1 This Law shall regulate the legal protection of inventions. The invention
More informationIP Innovations Class
IP Innovations Class Pitfalls for Patent Practitioners December 9, 2010 Presented by: Kris Doyle KDoyle@KilpatrickStockton.com 1 PRESERVING FOREIGN PATENT RIGHTS 2 1st Takeaway Absolute novelty is not
More informationAPPENDIX 8: DECLARATION OF INVENTION DECLARATION OF INVENTION
APPENDIX 8: DECLARATION OF INVENTION DECLARATION OF INVENTION The purpose of this form is to notify the and CUFA of your potential Invention and any relevant sponsorship and publication history. A copy
More informationCHAPTER 9-14 INVENTION DEVELOPMENT SERVICES CONTRACTS
CHAPTER 9-14 INVENTION DEVELOPMENT SERVICES CONTRACTS 9-14-01. Definitions. As used in this chapter, unless the context otherwise requires: 1. "Contract for invention development services" includes a contract
More informationTitle: The patentability criterion of inventive step / non-obviousness
Question Q217 National Group: Canada Title: The patentability criterion of inventive step / non-obviousness Contributors: Reporter within Working Committee: France Côté (chair) Philip Mendes Da Costa Don
More information5 Multiple Protection of Inventions
5 Multiple Protection of Inventions From the perspective of helping front runners efforts to obtain multiple protection rights and achieving international harmonization of systems, research studies were
More informationFrom Law of Patents, Layout Designs of Integrated Circuits, Plant Varieties, and Industrial Designs, Chapter Two:
Saudi Patent Office Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 2 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation of medicines...
More informationSecond medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: PHILIPPINES Second medical use or indication claims Mr. Alex Ferdinand FIDER Mr. Antonio Ray ORTIGUERA Angara Abello
More informationKevin C. Adam* I. INTRODUCTION
Structure or Function? AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc. and the Federal Circuit s Structure- Function Analysis of Functionally Defined Genus Claims Under Section 112 s Written Description
More informationAZERBAIJAN Law on Patent Date of Text (Enacted): July 25, 1997 ENTRY INTO FORCE: August 2, 1997
AZERBAIJAN Law on Patent Date of Text (Enacted): July 25, 1997 ENTRY INTO FORCE: August 2, 1997 TABLE OF CONTENTS Chapter I General Provisions Article 1 Basic notions Article 2 Legislation of the Republic
More informationPENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS
PENDING LEGISLATION REGULATING PATENT INFRINGEMENT SETTLEMENTS By Edward W. Correia* A number of bills have been introduced in the United States Congress this year that are intended to eliminate perceived
More informationCUSTOMER CONTRACT REQUIREMENTS A-160 HUMMINGBIRD CUSTOMER CONTRACT N
Page 1 of 5 CUSTOMER CONTRACT REQUIREMENTS A-160 HUMMINGBIRD CUSTOMER CONTRACT N00421-03-9-0001 (a) Patent Rights Note: The provisions of Patent Rights have been modified from the Prime Agreement to suitably
More informationSecond medical use or indication claims. [Please insert name last name in CAPITAL letters please]
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: New Zealand Second medical use or indication claims Michael BROWN, Partner Helen BELLCHAMBERS, Associate A J Park [Please
More informationUSPTO Trials: Understanding the Scope and Rules of Discovery
Client Alert August 21, 2012 USPTO Trials: Understanding the Scope and Rules of Discovery By Bryan P. Collins Discovery may perhaps be one of the most difficult items for clients, lawyers, and their adversaries
More informationChapter 16 of the above-mentioned Agreement establishes provisions relating to the need to respect and safeguard intellectual property rights;
LEGISLATIVE DECREE No. 1075 THE PRESIDENT OF THE REPUBLIC WHEREAS: The Trade Promotion Agreement between Peru and the United States of America approved by Legislative Resolution No. 28766, published in
More informationPatent Strategies Towards Generics
Patent Strategies Towards Generics Sean-Paul Brankin Crowell & Moring February 17, 2011 1 The Toolkit Strategic patenting (patent clusters) Life-cycle strategies (evergreening) Patent disputes and litigation
More informationPatent Law of the Republic of Kazakhstan
Patent Law of the Republic of Kazakhstan With an adoption of the Law On Amendments and Additions for some legislative acts concerning an intellectual property of the Republic of Kazakhstan March 2, 2007,
More informationA thesis submitted in partial fulfillment of the requirements for the degree in Master of Laws
Western University Scholarship@Western Electronic Thesis and Dissertation Repository July 2016 The Patented Medicines (Notice of Compliance) Regulations: An Examination of the Decision Making Patterns
More information3. Trials for Correction
3. Trials for Correction Q1: A request for a trial for correction may be filed by claim in a case where two or more claims need to be corrected. Are there any points
More informationLaw on the protection of inventions No. 50/2008 of the Republic of Moldova can be found at:
The answers to this questionnaire have been provided on behalf of: Country: Republic of Moldova... Office: The State Agency on Intellectual Property... Person to be contacted: Name: Cicinova Olga... Title:
More information